| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Kidney Transplantation | 84 | 2021 | 856 | 6.230 |
Why?
|
| Living Donors | 25 | 2021 | 339 | 4.000 |
Why?
|
| Graft Rejection | 82 | 2005 | 1076 | 2.830 |
Why?
|
| Tissue and Organ Procurement | 20 | 2019 | 360 | 2.480 |
Why?
|
| Immunosuppressive Agents | 45 | 2004 | 979 | 2.190 |
Why?
|
| Liver Transplantation | 60 | 2018 | 1175 | 2.160 |
Why?
|
| Pancreas Transplantation | 21 | 2006 | 104 | 1.890 |
Why?
|
| Graft Survival | 58 | 2016 | 908 | 1.870 |
Why?
|
| Tacrolimus | 24 | 2004 | 369 | 1.670 |
Why?
|
| Muromonab-CD3 | 26 | 1999 | 69 | 1.460 |
Why?
|
| Kidney Failure, Chronic | 9 | 2014 | 414 | 1.350 |
Why?
|
| Tissue Donors | 25 | 2016 | 505 | 1.230 |
Why?
|
| Physician-Patient Relations | 6 | 2015 | 624 | 1.160 |
Why?
|
| Antibodies, Monoclonal | 37 | 2001 | 1396 | 1.060 |
Why?
|
| Decision Making | 7 | 2015 | 670 | 1.020 |
Why?
|
| Informed Consent | 9 | 2021 | 275 | 1.000 |
Why?
|
| Transplantation, Homologous | 38 | 2005 | 995 | 0.910 |
Why?
|
| Attitude of Health Personnel | 9 | 2015 | 654 | 0.790 |
Why?
|
| Waiting Lists | 6 | 2015 | 187 | 0.780 |
Why?
|
| Organ Transplantation | 4 | 2016 | 283 | 0.780 |
Why?
|
| Cyclosporine | 18 | 2004 | 238 | 0.770 |
Why?
|
| Humans | 192 | 2021 | 89968 | 0.690 |
Why?
|
| Racism | 1 | 2021 | 92 | 0.650 |
Why?
|
| Transplantation, Heterologous | 10 | 1997 | 368 | 0.650 |
Why?
|
| Personal Autonomy | 3 | 2018 | 115 | 0.640 |
Why?
|
| Islets of Langerhans Transplantation | 12 | 1999 | 242 | 0.620 |
Why?
|
| General Practice | 2 | 2015 | 9 | 0.600 |
Why?
|
| Ethics, Research | 1 | 2018 | 52 | 0.590 |
Why?
|
| Kidney | 14 | 2016 | 1148 | 0.570 |
Why?
|
| Education, Medical, Undergraduate | 2 | 2013 | 182 | 0.540 |
Why?
|
| Time Factors | 35 | 2015 | 5359 | 0.540 |
Why?
|
| Social Justice | 2 | 2018 | 54 | 0.530 |
Why?
|
| Diabetes Mellitus, Experimental | 9 | 1999 | 191 | 0.520 |
Why?
|
| Patient Selection | 7 | 2018 | 682 | 0.510 |
Why?
|
| Patient Portals | 1 | 2015 | 18 | 0.490 |
Why?
|
| Patient Participation | 4 | 2011 | 226 | 0.490 |
Why?
|
| Risk Assessment | 8 | 2018 | 2327 | 0.470 |
Why?
|
| Health Services Accessibility | 2 | 2015 | 436 | 0.470 |
Why?
|
| Biomedical Research | 1 | 2018 | 405 | 0.450 |
Why?
|
| Tissue and Organ Harvesting | 1 | 2014 | 79 | 0.450 |
Why?
|
| Healthcare Disparities | 2 | 2015 | 432 | 0.440 |
Why?
|
| Registries | 2 | 2007 | 808 | 0.420 |
Why?
|
| Genetic Testing | 1 | 2016 | 542 | 0.400 |
Why?
|
| Efficiency, Organizational | 1 | 2012 | 59 | 0.400 |
Why?
|
| Adult | 67 | 2019 | 26822 | 0.400 |
Why?
|
| Coercion | 1 | 2012 | 15 | 0.400 |
Why?
|
| T-Lymphocytes | 19 | 2001 | 1221 | 0.390 |
Why?
|
| Clinical Clerkship | 1 | 2013 | 118 | 0.390 |
Why?
|
| Surgery, Plastic | 1 | 2012 | 42 | 0.380 |
Why?
|
| Moral Obligations | 1 | 2012 | 53 | 0.380 |
Why?
|
| Education, Professional | 1 | 2011 | 2 | 0.380 |
Why?
|
| Professional Misconduct | 1 | 2011 | 25 | 0.360 |
Why?
|
| Accreditation | 1 | 2011 | 61 | 0.360 |
Why?
|
| Ethics, Medical | 6 | 2016 | 306 | 0.360 |
Why?
|
| Decision Support Systems, Clinical | 2 | 2011 | 102 | 0.360 |
Why?
|
| Decision Support Techniques | 2 | 2015 | 168 | 0.350 |
Why?
|
| Health Behavior | 3 | 2016 | 185 | 0.350 |
Why?
|
| Male | 65 | 2019 | 42680 | 0.350 |
Why?
|
| Immunoconjugates | 9 | 2001 | 114 | 0.350 |
Why?
|
| Family Practice | 3 | 2006 | 83 | 0.340 |
Why?
|
| Mycophenolic Acid | 3 | 1998 | 84 | 0.330 |
Why?
|
| Adolescent | 33 | 2016 | 9342 | 0.330 |
Why?
|
| Burnout, Professional | 1 | 2011 | 102 | 0.320 |
Why?
|
| Female | 65 | 2021 | 46594 | 0.320 |
Why?
|
| Health Personnel | 1 | 2011 | 214 | 0.320 |
Why?
|
| Attitude to Health | 3 | 2008 | 222 | 0.310 |
Why?
|
| Antilymphocyte Serum | 13 | 1998 | 70 | 0.310 |
Why?
|
| Child | 36 | 2016 | 7244 | 0.310 |
Why?
|
| Intestine, Small | 6 | 2001 | 299 | 0.310 |
Why?
|
| Postoperative Complications | 20 | 2001 | 2314 | 0.290 |
Why?
|
| Middle Aged | 40 | 2019 | 26148 | 0.290 |
Why?
|
| Students, Medical | 2 | 2011 | 425 | 0.290 |
Why?
|
| Age Factors | 13 | 2015 | 1880 | 0.290 |
Why?
|
| United States | 13 | 2021 | 7108 | 0.290 |
Why?
|
| Cadaver | 12 | 2012 | 186 | 0.280 |
Why?
|
| Portal Vein | 7 | 2000 | 121 | 0.280 |
Why?
|
| Histocompatibility Antigens Class II | 6 | 1999 | 166 | 0.280 |
Why?
|
| Referral and Consultation | 2 | 2007 | 345 | 0.280 |
Why?
|
| Medical Staff, Hospital | 2 | 2010 | 109 | 0.270 |
Why?
|
| Reoperation | 20 | 2002 | 604 | 0.260 |
Why?
|
| Internet | 2 | 2010 | 323 | 0.260 |
Why?
|
| B7-1 Antigen | 4 | 2001 | 76 | 0.260 |
Why?
|
| Education, Medical, Graduate | 2 | 2007 | 402 | 0.250 |
Why?
|
| Transplantation, Isogeneic | 5 | 1999 | 40 | 0.250 |
Why?
|
| State Medicine | 1 | 2005 | 12 | 0.250 |
Why?
|
| Lymphoproliferative Disorders | 5 | 2001 | 111 | 0.250 |
Why?
|
| Histocompatibility Testing | 7 | 1999 | 137 | 0.240 |
Why?
|
| Algorithms | 3 | 2015 | 1913 | 0.240 |
Why?
|
| Truth Disclosure | 2 | 2015 | 93 | 0.240 |
Why?
|
| Child, Preschool | 27 | 2013 | 3773 | 0.240 |
Why?
|
| Follow-Up Studies | 25 | 2006 | 3680 | 0.230 |
Why?
|
| Skin Transplantation | 6 | 2000 | 184 | 0.230 |
Why?
|
| Cyclosporins | 9 | 1990 | 58 | 0.230 |
Why?
|
| Resource Allocation | 2 | 2011 | 65 | 0.230 |
Why?
|
| Duodenum | 3 | 2006 | 105 | 0.230 |
Why?
|
| Transplant Recipients | 2 | 2015 | 142 | 0.230 |
Why?
|
| CD3 Complex | 9 | 1995 | 134 | 0.230 |
Why?
|
| Drug Therapy | 1 | 2003 | 69 | 0.220 |
Why?
|
| Lymphocyte Activation | 14 | 2001 | 754 | 0.220 |
Why?
|
| Risk | 4 | 2016 | 657 | 0.220 |
Why?
|
| Azathioprine | 12 | 1998 | 124 | 0.210 |
Why?
|
| Cytokines | 4 | 1999 | 811 | 0.210 |
Why?
|
| Antigens, Differentiation | 10 | 2001 | 141 | 0.210 |
Why?
|
| Low Back Pain | 2 | 2014 | 41 | 0.210 |
Why?
|
| Organ Preservation | 8 | 1996 | 120 | 0.200 |
Why?
|
| Survival Rate | 13 | 1998 | 1899 | 0.200 |
Why?
|
| Infant | 20 | 2000 | 3191 | 0.200 |
Why?
|
| Antigens, CD | 14 | 2001 | 466 | 0.200 |
Why?
|
| Mice, SCID | 6 | 2000 | 259 | 0.190 |
Why?
|
| Biopsy | 11 | 2005 | 1184 | 0.190 |
Why?
|
| Recombinant Fusion Proteins | 4 | 2000 | 563 | 0.190 |
Why?
|
| Tumor Virus Infections | 3 | 2002 | 83 | 0.190 |
Why?
|
| Heart Transplantation | 5 | 2001 | 731 | 0.190 |
Why?
|
| Creatinine | 8 | 1999 | 294 | 0.180 |
Why?
|
| CD28 Antigens | 5 | 2001 | 90 | 0.180 |
Why?
|
| Policy Making | 2 | 2018 | 63 | 0.180 |
Why?
|
| Prednisone | 11 | 1998 | 255 | 0.180 |
Why?
|
| Receptors, Fc | 2 | 1999 | 32 | 0.170 |
Why?
|
| Mice | 28 | 2001 | 11851 | 0.170 |
Why?
|
| Program Evaluation | 3 | 2013 | 312 | 0.170 |
Why?
|
| Diabetes Complications | 2 | 2000 | 171 | 0.170 |
Why?
|
| Family | 4 | 2014 | 325 | 0.170 |
Why?
|
| Coronary Circulation | 1 | 2000 | 131 | 0.170 |
Why?
|
| Methylprednisolone | 7 | 1997 | 64 | 0.160 |
Why?
|
| Netherlands | 1 | 2019 | 24 | 0.160 |
Why?
|
| Animals | 45 | 2001 | 27528 | 0.160 |
Why?
|
| Lymphocyte Transfusion | 3 | 2000 | 41 | 0.160 |
Why?
|
| Transplantation | 2 | 1997 | 38 | 0.160 |
Why?
|
| Peptide Fragments | 2 | 2005 | 463 | 0.160 |
Why?
|
| Steroids | 2 | 1998 | 173 | 0.160 |
Why?
|
| Beneficence | 1 | 2018 | 34 | 0.150 |
Why?
|
| Maple Syrup Urine Disease | 1 | 2018 | 5 | 0.150 |
Why?
|
| Ethical Analysis | 1 | 2018 | 23 | 0.150 |
Why?
|
| Mice, Inbred C57BL | 15 | 2001 | 3252 | 0.150 |
Why?
|
| Acute Disease | 8 | 2003 | 846 | 0.150 |
Why?
|
| United Kingdom | 2 | 2011 | 165 | 0.150 |
Why?
|
| Enterococcus | 1 | 1998 | 35 | 0.150 |
Why?
|
| Herpesvirus 4, Human | 3 | 2001 | 120 | 0.150 |
Why?
|
| Proportional Hazards Models | 4 | 2016 | 848 | 0.150 |
Why?
|
| HLA Antigens | 3 | 1997 | 227 | 0.150 |
Why?
|
| Capillaries | 3 | 2005 | 90 | 0.150 |
Why?
|
| Research Subjects | 1 | 2018 | 73 | 0.150 |
Why?
|
| Australia | 2 | 2015 | 101 | 0.150 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 1998 | 51 | 0.150 |
Why?
|
| Vancomycin | 1 | 1998 | 73 | 0.140 |
Why?
|
| CD8-Positive T-Lymphocytes | 6 | 2001 | 600 | 0.140 |
Why?
|
| Transplantation, Heterotopic | 2 | 1995 | 46 | 0.140 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 1997 | 100 | 0.140 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2013 | 539 | 0.140 |
Why?
|
| Drug Therapy, Combination | 12 | 2004 | 785 | 0.140 |
Why?
|
| Rats, Inbred Lew | 6 | 1995 | 197 | 0.140 |
Why?
|
| Pilot Projects | 5 | 2014 | 872 | 0.140 |
Why?
|
| Retrospective Studies | 20 | 1999 | 9210 | 0.140 |
Why?
|
| Transplantation Chimera | 1 | 1996 | 81 | 0.140 |
Why?
|
| Rats | 13 | 1995 | 4048 | 0.140 |
Why?
|
| Risk Factors | 14 | 2018 | 5559 | 0.140 |
Why?
|
| Major Histocompatibility Complex | 5 | 1995 | 84 | 0.140 |
Why?
|
| Hepatectomy | 6 | 1996 | 172 | 0.130 |
Why?
|
| Apolipoprotein L1 | 1 | 2016 | 7 | 0.130 |
Why?
|
| Receptors, Antigen, T-Cell | 8 | 2001 | 395 | 0.130 |
Why?
|
| Diabetes Mellitus, Type 1 | 4 | 2006 | 565 | 0.130 |
Why?
|
| Diseases in Twins | 1 | 2016 | 65 | 0.130 |
Why?
|
| Actins | 1 | 1999 | 462 | 0.130 |
Why?
|
| Immunotherapy | 1 | 2001 | 698 | 0.130 |
Why?
|
| International Cooperation | 1 | 2016 | 127 | 0.130 |
Why?
|
| Islets of Langerhans | 3 | 1995 | 549 | 0.130 |
Why?
|
| Disclosure | 1 | 2016 | 109 | 0.130 |
Why?
|
| Diabetes Mellitus | 2 | 2004 | 744 | 0.130 |
Why?
|
| Congresses as Topic | 1 | 2016 | 115 | 0.130 |
Why?
|
| Treatment Outcome | 13 | 2015 | 8273 | 0.120 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 7 | 1994 | 97 | 0.120 |
Why?
|
| Liver | 12 | 2014 | 1211 | 0.120 |
Why?
|
| CD4-Positive T-Lymphocytes | 6 | 2001 | 450 | 0.120 |
Why?
|
| History, 20th Century | 1 | 2016 | 314 | 0.120 |
Why?
|
| Glomerulonephritis, Membranous | 1 | 1994 | 23 | 0.120 |
Why?
|
| C-Peptide | 3 | 1999 | 179 | 0.120 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2015 | 855 | 0.120 |
Why?
|
| Health Policy | 1 | 2016 | 188 | 0.120 |
Why?
|
| Geography | 1 | 2015 | 227 | 0.120 |
Why?
|
| Physicians | 3 | 2014 | 692 | 0.120 |
Why?
|
| Aged | 13 | 2015 | 19254 | 0.120 |
Why?
|
| Jejunum | 3 | 2006 | 80 | 0.110 |
Why?
|
| Crigler-Najjar Syndrome | 1 | 1993 | 3 | 0.110 |
Why?
|
| Intestines | 4 | 2001 | 416 | 0.110 |
Why?
|
| Patient Satisfaction | 2 | 2014 | 460 | 0.110 |
Why?
|
| End Stage Liver Disease | 1 | 2014 | 61 | 0.110 |
Why?
|
| Survival Analysis | 7 | 2000 | 1498 | 0.110 |
Why?
|
| Continuity of Patient Care | 1 | 2015 | 172 | 0.110 |
Why?
|
| Patient Preference | 1 | 2014 | 111 | 0.110 |
Why?
|
| Bone Marrow Transplantation | 1 | 1994 | 283 | 0.110 |
Why?
|
| Mice, Knockout | 9 | 2001 | 2015 | 0.110 |
Why?
|
| Health Equity | 1 | 2015 | 96 | 0.110 |
Why?
|
| Patient Education as Topic | 2 | 2006 | 364 | 0.110 |
Why?
|
| Health Status | 1 | 2015 | 371 | 0.110 |
Why?
|
| England | 2 | 2003 | 38 | 0.110 |
Why?
|
| Behavior | 1 | 2013 | 85 | 0.110 |
Why?
|
| Practice Guidelines as Topic | 3 | 2016 | 1054 | 0.110 |
Why?
|
| Mice, Inbred C3H | 8 | 2001 | 371 | 0.110 |
Why?
|
| CD8 Antigens | 5 | 1999 | 82 | 0.100 |
Why?
|
| B-Lymphocytes | 3 | 1990 | 740 | 0.100 |
Why?
|
| Reproducibility of Results | 2 | 2011 | 2767 | 0.100 |
Why?
|
| Peer Group | 1 | 2013 | 86 | 0.100 |
Why?
|
| Drainage | 4 | 1998 | 165 | 0.100 |
Why?
|
| Insulin | 4 | 1999 | 1148 | 0.100 |
Why?
|
| Nephritis, Interstitial | 3 | 2002 | 44 | 0.100 |
Why?
|
| HLA-D Antigens | 2 | 1995 | 20 | 0.100 |
Why?
|
| Anti-Bacterial Agents | 1 | 1998 | 798 | 0.100 |
Why?
|
| Mentors | 1 | 2013 | 90 | 0.100 |
Why?
|
| Career Choice | 1 | 2013 | 148 | 0.100 |
Why?
|
| Prospective Studies | 6 | 2016 | 4331 | 0.100 |
Why?
|
| Biopsy, Needle | 3 | 1998 | 231 | 0.100 |
Why?
|
| Residence Characteristics | 1 | 2013 | 203 | 0.100 |
Why?
|
| Data Interpretation, Statistical | 1 | 2013 | 303 | 0.090 |
Why?
|
| Genotype | 1 | 2016 | 1853 | 0.090 |
Why?
|
| Educational Measurement | 1 | 2013 | 231 | 0.090 |
Why?
|
| Surgeons | 1 | 2015 | 249 | 0.090 |
Why?
|
| Surveys and Questionnaires | 5 | 2015 | 2655 | 0.090 |
Why?
|
| RNA, Messenger | 3 | 2001 | 2026 | 0.090 |
Why?
|
| Siblings | 2 | 2008 | 110 | 0.090 |
Why?
|
| Recurrence | 5 | 1998 | 1145 | 0.090 |
Why?
|
| Abatacept | 9 | 2001 | 86 | 0.090 |
Why?
|
| Prescriptions | 1 | 2010 | 23 | 0.090 |
Why?
|
| Cross-Cultural Comparison | 1 | 2010 | 34 | 0.090 |
Why?
|
| Blood Glucose | 5 | 1996 | 837 | 0.090 |
Why?
|
| Professional Competence | 1 | 2011 | 69 | 0.090 |
Why?
|
| Biliary Tract Diseases | 3 | 1997 | 36 | 0.090 |
Why?
|
| Pancreas | 7 | 1999 | 253 | 0.090 |
Why?
|
| CTLA-4 Antigen | 9 | 2001 | 140 | 0.090 |
Why?
|
| Lymphocyte Culture Test, Mixed | 5 | 1997 | 73 | 0.090 |
Why?
|
| Focus Groups | 2 | 2010 | 177 | 0.090 |
Why?
|
| Physical Therapy Modalities | 1 | 2011 | 84 | 0.090 |
Why?
|
| Infant, Newborn | 4 | 1998 | 2499 | 0.090 |
Why?
|
| Directed Tissue Donation | 2 | 2006 | 7 | 0.090 |
Why?
|
| Learning | 1 | 2013 | 286 | 0.090 |
Why?
|
| Immune Tolerance | 4 | 2001 | 341 | 0.090 |
Why?
|
| Health Services Needs and Demand | 1 | 2010 | 108 | 0.090 |
Why?
|
| Renal Veins | 1 | 1989 | 28 | 0.080 |
Why?
|
| Choice Behavior | 1 | 2011 | 160 | 0.080 |
Why?
|
| Drug Resistance | 5 | 1996 | 232 | 0.080 |
Why?
|
| Transplantation Tolerance | 2 | 2001 | 138 | 0.080 |
Why?
|
| Renal Artery | 1 | 1989 | 52 | 0.080 |
Why?
|
| Costs and Cost Analysis | 3 | 1997 | 153 | 0.080 |
Why?
|
| Influenza Vaccines | 1 | 2010 | 150 | 0.080 |
Why?
|
| Arteriovenous Fistula | 1 | 1989 | 53 | 0.080 |
Why?
|
| Liver Function Tests | 4 | 1997 | 92 | 0.080 |
Why?
|
| Cytomegalovirus Infections | 4 | 1996 | 150 | 0.080 |
Why?
|
| Chicago | 6 | 2000 | 1434 | 0.080 |
Why?
|
| Minors | 1 | 2008 | 15 | 0.080 |
Why?
|
| Drug Administration Schedule | 5 | 1998 | 865 | 0.080 |
Why?
|
| Palpation | 1 | 2008 | 18 | 0.080 |
Why?
|
| Parental Consent | 1 | 2008 | 35 | 0.080 |
Why?
|
| Young Adult | 3 | 2015 | 6410 | 0.080 |
Why?
|
| Mice, Inbred Strains | 5 | 2000 | 308 | 0.080 |
Why?
|
| Veins | 1 | 1988 | 95 | 0.080 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2010 | 608 | 0.080 |
Why?
|
| Genes, MHC Class II | 3 | 1998 | 30 | 0.080 |
Why?
|
| Hot Temperature | 1 | 1989 | 207 | 0.080 |
Why?
|
| Physicians, Family | 1 | 2008 | 39 | 0.080 |
Why?
|
| Professional Practice | 1 | 2008 | 46 | 0.080 |
Why?
|
| Lymphocytes | 2 | 1995 | 468 | 0.070 |
Why?
|
| Trans-Activators | 2 | 2001 | 443 | 0.070 |
Why?
|
| Education, Medical | 1 | 2011 | 243 | 0.070 |
Why?
|
| Swine | 4 | 1984 | 590 | 0.070 |
Why?
|
| Pelvis | 1 | 2008 | 96 | 0.070 |
Why?
|
| Histocompatibility Antigens Class I | 4 | 1999 | 201 | 0.070 |
Why?
|
| ABO Blood-Group System | 2 | 2006 | 58 | 0.070 |
Why?
|
| Swine, Miniature | 2 | 1984 | 50 | 0.070 |
Why?
|
| Arteries | 1 | 1988 | 179 | 0.070 |
Why?
|
| Clinical Competence | 1 | 2013 | 796 | 0.070 |
Why?
|
| Social Responsibility | 1 | 2007 | 57 | 0.070 |
Why?
|
| Immunoglobulin G | 5 | 1997 | 469 | 0.070 |
Why?
|
| Monitoring, Physiologic | 2 | 1989 | 266 | 0.070 |
Why?
|
| Confidentiality | 3 | 2015 | 79 | 0.070 |
Why?
|
| Flow Cytometry | 5 | 1994 | 690 | 0.070 |
Why?
|
| Influenza, Human | 1 | 2010 | 340 | 0.070 |
Why?
|
| Cryopreservation | 3 | 1996 | 70 | 0.070 |
Why?
|
| Antigens, Surface | 1 | 1987 | 102 | 0.070 |
Why?
|
| Hematopoietic Stem Cells | 1 | 1989 | 305 | 0.070 |
Why?
|
| Curriculum | 2 | 2010 | 573 | 0.070 |
Why?
|
| Embolization, Therapeutic | 1 | 1989 | 265 | 0.070 |
Why?
|
| Interleukin-2 | 5 | 2000 | 241 | 0.070 |
Why?
|
| Interviews as Topic | 1 | 2007 | 344 | 0.070 |
Why?
|
| Bilirubin | 2 | 1998 | 131 | 0.060 |
Why?
|
| Tumor Necrosis Factor-alpha | 6 | 2001 | 700 | 0.060 |
Why?
|
| Histocompatibility | 1 | 2006 | 65 | 0.060 |
Why?
|
| Incidence | 7 | 1998 | 1603 | 0.060 |
Why?
|
| Data Collection | 3 | 2014 | 377 | 0.060 |
Why?
|
| Prognosis | 5 | 2011 | 3798 | 0.060 |
Why?
|
| Attitude | 2 | 2016 | 130 | 0.060 |
Why?
|
| Liver Diseases | 4 | 1991 | 242 | 0.060 |
Why?
|
| Complement C4b | 1 | 2005 | 32 | 0.060 |
Why?
|
| Iliac Vein | 2 | 1996 | 32 | 0.060 |
Why?
|
| Transplantation Immunology | 2 | 1997 | 81 | 0.060 |
Why?
|
| Hepatic Artery | 3 | 1996 | 84 | 0.060 |
Why?
|
| Calcium Channel Agonists | 1 | 2004 | 13 | 0.060 |
Why?
|
| Treatment Failure | 2 | 1997 | 278 | 0.060 |
Why?
|
| Intraoperative Care | 3 | 1989 | 85 | 0.060 |
Why?
|
| Hospitals, University | 3 | 1997 | 196 | 0.060 |
Why?
|
| Minority Groups | 1 | 2006 | 147 | 0.060 |
Why?
|
| Bone Diseases, Metabolic | 1 | 2004 | 33 | 0.060 |
Why?
|
| Therapeutic Human Experimentation | 2 | 1997 | 20 | 0.060 |
Why?
|
| Multivariate Analysis | 2 | 2015 | 983 | 0.060 |
Why?
|
| Urinary Bladder | 2 | 1996 | 248 | 0.060 |
Why?
|
| Thrombosis | 3 | 1998 | 302 | 0.060 |
Why?
|
| Patient-Centered Care | 1 | 2006 | 210 | 0.060 |
Why?
|
| Calcitriol | 1 | 2004 | 173 | 0.060 |
Why?
|
| Anastomosis, Surgical | 5 | 2006 | 277 | 0.060 |
Why?
|
| Models, Theoretical | 1 | 2006 | 493 | 0.050 |
Why?
|
| Dendritic Cells | 1 | 1987 | 451 | 0.050 |
Why?
|
| Antibodies, Anti-Idiotypic | 4 | 1991 | 44 | 0.050 |
Why?
|
| Th1 Cells | 2 | 2001 | 166 | 0.050 |
Why?
|
| Th2 Cells | 2 | 2001 | 147 | 0.050 |
Why?
|
| Blood Platelets | 1 | 2003 | 150 | 0.050 |
Why?
|
| Surgical Wound Infection | 4 | 1998 | 202 | 0.050 |
Why?
|
| Actuarial Analysis | 3 | 1997 | 66 | 0.050 |
Why?
|
| Schools, Medical | 1 | 2003 | 136 | 0.050 |
Why?
|
| BK Virus | 1 | 2002 | 24 | 0.050 |
Why?
|
| Hypovolemia | 1 | 2001 | 3 | 0.050 |
Why?
|
| Patient Compliance | 1 | 2003 | 230 | 0.050 |
Why?
|
| Polyomavirus Infections | 1 | 2002 | 29 | 0.050 |
Why?
|
| Academic Medical Centers | 2 | 2014 | 384 | 0.050 |
Why?
|
| Cytomegalovirus | 2 | 1995 | 79 | 0.050 |
Why?
|
| Receptors, Interleukin-2 | 5 | 1994 | 67 | 0.050 |
Why?
|
| Lymphotoxin-alpha | 1 | 2001 | 44 | 0.050 |
Why?
|
| Calcium | 2 | 2004 | 1179 | 0.050 |
Why?
|
| Kidney Glomerulus | 2 | 2003 | 122 | 0.050 |
Why?
|
| Biological Availability | 2 | 1998 | 91 | 0.050 |
Why?
|
| Risk-Taking | 1 | 2002 | 155 | 0.050 |
Why?
|
| CD40 Antigens | 1 | 2001 | 44 | 0.050 |
Why?
|
| Methylprednisolone Hemisuccinate | 2 | 1998 | 10 | 0.050 |
Why?
|
| CD40 Ligand | 1 | 2001 | 69 | 0.050 |
Why?
|
| Therapeutic Equivalency | 1 | 2000 | 16 | 0.050 |
Why?
|
| Quality Assurance, Health Care | 1 | 2002 | 225 | 0.050 |
Why?
|
| Consumer Product Safety | 1 | 2000 | 11 | 0.050 |
Why?
|
| Pediatrics | 3 | 2008 | 360 | 0.050 |
Why?
|
| Blood Transfusion | 3 | 1999 | 171 | 0.050 |
Why?
|
| Plasma Cells | 1 | 2001 | 85 | 0.040 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 1999 | 374 | 0.040 |
Why?
|
| Femoral Vein | 2 | 1999 | 39 | 0.040 |
Why?
|
| Antibodies, Viral | 2 | 1995 | 311 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 1 | 2000 | 168 | 0.040 |
Why?
|
| Length of Stay | 2 | 1997 | 749 | 0.040 |
Why?
|
| Analysis of Variance | 3 | 1998 | 899 | 0.040 |
Why?
|
| Immunoenzyme Techniques | 3 | 2003 | 303 | 0.040 |
Why?
|
| Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 1999 | 18 | 0.040 |
Why?
|
| Recombinant Proteins | 2 | 2000 | 1008 | 0.040 |
Why?
|
| Arterioles | 1 | 1999 | 22 | 0.040 |
Why?
|
| Half-Life | 1 | 1999 | 97 | 0.040 |
Why?
|
| Rats, Inbred Strains | 3 | 1989 | 312 | 0.040 |
Why?
|
| Ischemia | 3 | 1996 | 253 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 1999 | 1929 | 0.040 |
Why?
|
| Gallbladder | 2 | 1997 | 31 | 0.040 |
Why?
|
| Ganciclovir | 2 | 1997 | 49 | 0.040 |
Why?
|
| Protein Isoforms | 1 | 2000 | 278 | 0.040 |
Why?
|
| Adrenal Cortex Hormones | 2 | 1998 | 270 | 0.040 |
Why?
|
| Signal Transduction | 5 | 2001 | 3404 | 0.040 |
Why?
|
| Postoperative Care | 1 | 1999 | 231 | 0.040 |
Why?
|
| Volition | 1 | 2018 | 15 | 0.040 |
Why?
|
| Glucocorticoids | 2 | 1997 | 357 | 0.040 |
Why?
|
| Hemoperfusion | 2 | 1988 | 5 | 0.040 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 1999 | 241 | 0.040 |
Why?
|
| Drug Resistance, Microbial | 1 | 1998 | 75 | 0.040 |
Why?
|
| Communication | 1 | 2002 | 461 | 0.040 |
Why?
|
| Spleen | 2 | 2000 | 433 | 0.040 |
Why?
|
| Gallbladder Diseases | 1 | 1998 | 23 | 0.040 |
Why?
|
| Genes, T-Cell Receptor beta | 1 | 1997 | 8 | 0.040 |
Why?
|
| Membrane Glycoproteins | 2 | 2001 | 431 | 0.040 |
Why?
|
| DNA-Binding Proteins | 2 | 2001 | 1244 | 0.040 |
Why?
|
| Intercellular Adhesion Molecule-1 | 2 | 1994 | 74 | 0.040 |
Why?
|
| Human Body | 1 | 1997 | 7 | 0.040 |
Why?
|
| Anti-Inflammatory Agents | 2 | 1997 | 346 | 0.040 |
Why?
|
| Urinary Retention | 1 | 1997 | 42 | 0.040 |
Why?
|
| Complement C3 | 1 | 1997 | 58 | 0.040 |
Why?
|
| Nephrectomy | 3 | 2008 | 291 | 0.040 |
Why?
|
| Femoral Neoplasms | 1 | 1997 | 23 | 0.040 |
Why?
|
| Digestive System Surgical Procedures | 1 | 1998 | 128 | 0.040 |
Why?
|
| Renal Insufficiency | 1 | 1998 | 98 | 0.040 |
Why?
|
| Chondrosarcoma | 1 | 1997 | 50 | 0.040 |
Why?
|
| Preoperative Care | 1 | 1999 | 395 | 0.040 |
Why?
|
| Histiocytosis, Langerhans-Cell | 1 | 1997 | 24 | 0.040 |
Why?
|
| T-Lymphocyte Subsets | 2 | 2001 | 276 | 0.040 |
Why?
|
| Amylases | 2 | 1994 | 14 | 0.040 |
Why?
|
| Fibrin | 1 | 1997 | 86 | 0.040 |
Why?
|
| Bone Transplantation | 1 | 1997 | 67 | 0.040 |
Why?
|
| Quality of Life | 2 | 1996 | 1682 | 0.040 |
Why?
|
| Chronic Disease | 2 | 1999 | 958 | 0.030 |
Why?
|
| Bacteremia | 1 | 1998 | 103 | 0.030 |
Why?
|
| Occlusive Dressings | 1 | 1996 | 7 | 0.030 |
Why?
|
| Biliary Atresia | 3 | 1992 | 22 | 0.030 |
Why?
|
| Ileum | 1 | 1997 | 168 | 0.030 |
Why?
|
| Perfusion | 2 | 1989 | 253 | 0.030 |
Why?
|
| Myocardium | 1 | 2000 | 573 | 0.030 |
Why?
|
| Fractures, Bone | 1 | 1998 | 133 | 0.030 |
Why?
|
| Polytetrafluoroethylene | 1 | 1996 | 74 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2000 | 841 | 0.030 |
Why?
|
| Homozygote | 1 | 1996 | 201 | 0.030 |
Why?
|
| Graft Occlusion, Vascular | 1 | 1996 | 99 | 0.030 |
Why?
|
| Respiratory Insufficiency | 1 | 1998 | 162 | 0.030 |
Why?
|
| Hospitalization | 1 | 2002 | 888 | 0.030 |
Why?
|
| Neutrophils | 1 | 1997 | 311 | 0.030 |
Why?
|
| Clinical Decision-Making | 1 | 2018 | 281 | 0.030 |
Why?
|
| Cold Temperature | 3 | 1996 | 160 | 0.030 |
Why?
|
| Bone Diseases | 1 | 1995 | 57 | 0.030 |
Why?
|
| Italy | 1 | 2015 | 108 | 0.030 |
Why?
|
| Antibodies | 1 | 1997 | 353 | 0.030 |
Why?
|
| Life Expectancy | 1 | 2015 | 88 | 0.030 |
Why?
|
| Diabetic Nephropathies | 1 | 1995 | 87 | 0.030 |
Why?
|
| Receptor-CD3 Complex, Antigen, T-Cell | 1 | 1995 | 4 | 0.030 |
Why?
|
| Rats, Inbred WF | 1 | 1995 | 11 | 0.030 |
Why?
|
| Illinois | 1 | 1997 | 485 | 0.030 |
Why?
|
| Unsafe Sex | 1 | 2015 | 45 | 0.030 |
Why?
|
| Salvage Therapy | 1 | 1996 | 230 | 0.030 |
Why?
|
| Monitoring, Immunologic | 1 | 1995 | 17 | 0.030 |
Why?
|
| Interleukin-5 | 1 | 1995 | 36 | 0.030 |
Why?
|
| Safety | 1 | 1995 | 145 | 0.030 |
Why?
|
| Bacterial Infections | 3 | 1992 | 184 | 0.030 |
Why?
|
| Cells, Cultured | 3 | 1995 | 2887 | 0.030 |
Why?
|
| Lymphokines | 2 | 1991 | 75 | 0.030 |
Why?
|
| Extremities | 1 | 1995 | 174 | 0.030 |
Why?
|
| Blood Vessel Prosthesis | 1 | 1996 | 244 | 0.030 |
Why?
|
| Rats, Inbred ACI | 1 | 1994 | 25 | 0.030 |
Why?
|
| Graft vs Host Disease | 1 | 1996 | 358 | 0.030 |
Why?
|
| Gastrointestinal Hemorrhage | 2 | 1989 | 239 | 0.030 |
Why?
|
| Interleukin-10 | 1 | 1995 | 155 | 0.030 |
Why?
|
| Solutions | 2 | 1991 | 86 | 0.030 |
Why?
|
| Choledochostomy | 2 | 1992 | 8 | 0.030 |
Why?
|
| Histocompatibility Antigens | 2 | 1984 | 38 | 0.030 |
Why?
|
| Immunization Schedule | 2 | 2010 | 21 | 0.030 |
Why?
|
| Mental Health | 1 | 2015 | 180 | 0.030 |
Why?
|
| Thymus Gland | 1 | 1995 | 197 | 0.030 |
Why?
|
| Kidney Diseases | 1 | 1996 | 320 | 0.030 |
Why?
|
| Immunoglobulin Fab Fragments | 2 | 1991 | 85 | 0.030 |
Why?
|
| Cell Separation | 1 | 1994 | 199 | 0.030 |
Why?
|
| Immunoglobulin Fc Fragments | 3 | 2001 | 19 | 0.030 |
Why?
|
| Serum Albumin | 2 | 1988 | 128 | 0.030 |
Why?
|
| Kinetics | 2 | 1995 | 1534 | 0.030 |
Why?
|
| Cardiovascular System | 2 | 1993 | 63 | 0.030 |
Why?
|
| Cell Adhesion Molecules | 1 | 1994 | 167 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2014 | 371 | 0.030 |
Why?
|
| Common Bile Duct Diseases | 1 | 1992 | 9 | 0.030 |
Why?
|
| Saphenous Vein | 1 | 1993 | 61 | 0.030 |
Why?
|
| Hyperglycemia | 1 | 1994 | 172 | 0.030 |
Why?
|
| Uranium Compounds | 1 | 1992 | 1 | 0.030 |
Why?
|
| Uranium | 1 | 1992 | 8 | 0.030 |
Why?
|
| Immunotherapy, Adoptive | 1 | 1994 | 197 | 0.030 |
Why?
|
| Interferon-gamma | 4 | 2000 | 449 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 3 | 2001 | 1091 | 0.030 |
Why?
|
| Immunoglobulin Idiotypes | 1 | 1992 | 12 | 0.030 |
Why?
|
| Allopurinol | 2 | 1991 | 77 | 0.030 |
Why?
|
| Syndrome | 1 | 1993 | 451 | 0.020 |
Why?
|
| Central Nervous System | 1 | 1993 | 153 | 0.020 |
Why?
|
| Ultrasonography | 2 | 1998 | 720 | 0.020 |
Why?
|
| Immunohistochemistry | 2 | 2005 | 1801 | 0.020 |
Why?
|
| Phosphates | 1 | 1992 | 161 | 0.020 |
Why?
|
| Communicable Diseases | 1 | 1992 | 63 | 0.020 |
Why?
|
| Nausea | 1 | 1993 | 175 | 0.020 |
Why?
|
| Gram-Negative Aerobic Bacteria | 1 | 1991 | 2 | 0.020 |
Why?
|
| Organ Preservation Solutions | 1 | 1991 | 31 | 0.020 |
Why?
|
| Abdominal Pain | 1 | 1992 | 142 | 0.020 |
Why?
|
| Vomiting | 1 | 1993 | 195 | 0.020 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 1998 | 594 | 0.020 |
Why?
|
| STAT4 Transcription Factor | 2 | 2001 | 10 | 0.020 |
Why?
|
| Arterial Occlusive Diseases | 1 | 1992 | 110 | 0.020 |
Why?
|
| STAT6 Transcription Factor | 2 | 2001 | 28 | 0.020 |
Why?
|
| Blood Volume | 3 | 1988 | 49 | 0.020 |
Why?
|
| Substance-Related Disorders | 1 | 2015 | 420 | 0.020 |
Why?
|
| Arteriosclerosis | 1 | 1991 | 112 | 0.020 |
Why?
|
| Renal Circulation | 1 | 1990 | 48 | 0.020 |
Why?
|
| Ethical Review | 1 | 1990 | 8 | 0.020 |
Why?
|
| Biliary Tract Surgical Procedures | 1 | 1990 | 16 | 0.020 |
Why?
|
| Aged, 80 and over | 2 | 2015 | 6783 | 0.020 |
Why?
|
| Adoptive Transfer | 2 | 2001 | 169 | 0.020 |
Why?
|
| Hyperlipidemias | 1 | 1991 | 92 | 0.020 |
Why?
|
| Liver Cirrhosis | 2 | 1990 | 257 | 0.020 |
Why?
|
| Lipoproteins | 1 | 1991 | 136 | 0.020 |
Why?
|
| In Vitro Techniques | 4 | 1994 | 996 | 0.020 |
Why?
|
| Injections, Intraperitoneal | 2 | 2000 | 101 | 0.020 |
Why?
|
| Immunoglobulin M | 2 | 1988 | 164 | 0.020 |
Why?
|
| Lymph Nodes | 2 | 1990 | 550 | 0.020 |
Why?
|
| Dissection | 1 | 1989 | 44 | 0.020 |
Why?
|
| Cholelithiasis | 2 | 1965 | 35 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2010 | 281 | 0.020 |
Why?
|
| Embolism | 1 | 1989 | 33 | 0.020 |
Why?
|
| Portasystemic Shunt, Surgical | 1 | 1989 | 12 | 0.020 |
Why?
|
| Cardiovascular Diseases | 1 | 1995 | 716 | 0.020 |
Why?
|
| Esophageal and Gastric Varices | 1 | 1989 | 35 | 0.020 |
Why?
|
| Transfusion Reaction | 1 | 1988 | 17 | 0.020 |
Why?
|
| Alprostadil | 1 | 1988 | 25 | 0.020 |
Why?
|
| B7-2 Antigen | 2 | 2001 | 40 | 0.020 |
Why?
|
| Hypertension, Portal | 1 | 1989 | 46 | 0.020 |
Why?
|
| Macaca fascicularis | 2 | 1999 | 109 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2013 | 1102 | 0.020 |
Why?
|
| Bile Duct Neoplasms | 1 | 1989 | 95 | 0.020 |
Why?
|
| ROC Curve | 1 | 2011 | 778 | 0.020 |
Why?
|
| Guideline Adherence | 1 | 2010 | 234 | 0.020 |
Why?
|
| Pancreatitis | 2 | 1963 | 86 | 0.020 |
Why?
|
| Graft Enhancement, Immunologic | 2 | 2000 | 13 | 0.020 |
Why?
|
| Nitroblue Tetrazolium | 1 | 1988 | 2 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2011 | 467 | 0.020 |
Why?
|
| Tetrazolium Salts | 1 | 1988 | 12 | 0.020 |
Why?
|
| Meningitis, Aseptic | 1 | 1988 | 8 | 0.020 |
Why?
|
| Biomarkers | 1 | 1995 | 1778 | 0.020 |
Why?
|
| Drug Evaluation | 1 | 1988 | 137 | 0.020 |
Why?
|
| Diagnosis, Differential | 2 | 1999 | 1607 | 0.020 |
Why?
|
| Renal Dialysis | 1 | 1991 | 337 | 0.020 |
Why?
|
| Bioethics | 1 | 2008 | 35 | 0.020 |
Why?
|
| Alkaline Phosphatase | 1 | 1988 | 132 | 0.020 |
Why?
|
| Blood Volume Determination | 2 | 1957 | 14 | 0.020 |
Why?
|
| Bile | 2 | 1998 | 58 | 0.020 |
Why?
|
| Radioisotopes | 2 | 1957 | 43 | 0.020 |
Why?
|
| Superoxide Dismutase | 1 | 1988 | 177 | 0.020 |
Why?
|
| Physical Examination | 1 | 2008 | 149 | 0.020 |
Why?
|
| Diagnosis-Related Groups | 1 | 1987 | 21 | 0.020 |
Why?
|
| Stress, Physiological | 1 | 1989 | 232 | 0.020 |
Why?
|
| Heart Diseases | 1 | 1989 | 302 | 0.020 |
Why?
|
| Lymphocyte Depletion | 2 | 1998 | 98 | 0.020 |
Why?
|
| Hepatic Veins | 2 | 2000 | 26 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 1987 | 323 | 0.020 |
Why?
|
| Pulmonary Embolism | 1 | 1989 | 232 | 0.020 |
Why?
|
| Lung | 1 | 1993 | 1292 | 0.020 |
Why?
|
| Carcinoma | 1 | 1989 | 438 | 0.020 |
Why?
|
| T-Lymphocytes, Cytotoxic | 3 | 1992 | 319 | 0.020 |
Why?
|
| CD4 Antigens | 2 | 1999 | 83 | 0.020 |
Why?
|
| Medicare | 1 | 1989 | 427 | 0.020 |
Why?
|
| Hemorrhage | 1 | 1988 | 287 | 0.020 |
Why?
|
| Organ Size | 3 | 1992 | 372 | 0.020 |
Why?
|
| Seizures | 1 | 1988 | 308 | 0.020 |
Why?
|
| Clinical Trials as Topic | 2 | 1989 | 1134 | 0.020 |
Why?
|
| Cholecystectomy | 1 | 1965 | 23 | 0.020 |
Why?
|
| Celiac Artery | 1 | 1965 | 25 | 0.020 |
Why?
|
| Radius | 1 | 2004 | 31 | 0.010 |
Why?
|
| Femur Neck | 1 | 2004 | 44 | 0.010 |
Why?
|
| Iliac Artery | 1 | 1965 | 41 | 0.010 |
Why?
|
| Laparotomy | 1 | 1965 | 68 | 0.010 |
Why?
|
| Aneurysm | 1 | 1965 | 60 | 0.010 |
Why?
|
| Societies, Medical | 1 | 2008 | 584 | 0.010 |
Why?
|
| Intraoperative Period | 2 | 1998 | 91 | 0.010 |
Why?
|
| Absorptiometry, Photon | 1 | 2004 | 102 | 0.010 |
Why?
|
| Echocardiography | 1 | 1989 | 944 | 0.010 |
Why?
|
| Isoantibodies | 2 | 1997 | 120 | 0.010 |
Why?
|
| Ampulla of Vater | 1 | 1963 | 23 | 0.010 |
Why?
|
| Vascular Surgical Procedures | 1 | 1965 | 149 | 0.010 |
Why?
|
| Lumbar Vertebrae | 1 | 2004 | 152 | 0.010 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 1984 | 215 | 0.010 |
Why?
|
| Integrin beta3 | 1 | 2003 | 32 | 0.010 |
Why?
|
| Bone Density | 1 | 2004 | 211 | 0.010 |
Why?
|
| Antigens, CD34 | 1 | 2003 | 159 | 0.010 |
Why?
|
| Pancreatitis, Chronic | 1 | 1963 | 61 | 0.010 |
Why?
|
| Kidney Tubules | 1 | 2003 | 92 | 0.010 |
Why?
|
| Crosses, Genetic | 2 | 1999 | 171 | 0.010 |
Why?
|
| Vitamin D | 1 | 2004 | 269 | 0.010 |
Why?
|
| Receptors, Tumor Necrosis Factor, Member 14 | 1 | 2001 | 7 | 0.010 |
Why?
|
| Tumor Necrosis Factor Ligand Superfamily Member 14 | 1 | 2001 | 14 | 0.010 |
Why?
|
| Receptors, Virus | 1 | 2001 | 75 | 0.010 |
Why?
|
| Anastomosis, Roux-en-Y | 2 | 1992 | 26 | 0.010 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2001 | 90 | 0.010 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 2 | 1992 | 111 | 0.010 |
Why?
|
| Surgical Procedures, Operative | 1 | 1963 | 206 | 0.010 |
Why?
|
| Endothelium, Vascular | 1 | 2003 | 435 | 0.010 |
Why?
|
| Cell Count | 1 | 2001 | 199 | 0.010 |
Why?
|
| Genes, Immunoglobulin | 1 | 2001 | 111 | 0.010 |
Why?
|
| Binding Sites, Antibody | 2 | 1992 | 49 | 0.010 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2001 | 55 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 2001 | 313 | 0.010 |
Why?
|
| Antigen-Presenting Cells | 1 | 2001 | 142 | 0.010 |
Why?
|
| Immunity, Cellular | 1 | 2001 | 178 | 0.010 |
Why?
|
| Gene Rearrangement | 1 | 2001 | 177 | 0.010 |
Why?
|
| Blood Preservation | 1 | 1999 | 10 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2002 | 919 | 0.010 |
Why?
|
| Virus Diseases | 2 | 1992 | 99 | 0.010 |
Why?
|
| RNA, Viral | 1 | 2001 | 318 | 0.010 |
Why?
|
| Streptozocin | 1 | 1999 | 55 | 0.010 |
Why?
|
| Insulin Infusion Systems | 1 | 1999 | 37 | 0.010 |
Why?
|
| Vascular Patency | 1 | 1999 | 129 | 0.010 |
Why?
|
| Glucose Tolerance Test | 1 | 1999 | 227 | 0.010 |
Why?
|
| Fistula | 1 | 1959 | 42 | 0.010 |
Why?
|
| Iohexol | 1 | 1998 | 24 | 0.010 |
Why?
|
| Amoxicillin | 1 | 1998 | 12 | 0.010 |
Why?
|
| Cefotaxime | 1 | 1998 | 5 | 0.010 |
Why?
|
| Shock | 1 | 1998 | 44 | 0.010 |
Why?
|
| Penicillins | 1 | 1998 | 20 | 0.010 |
Why?
|
| Genes, MHC Class I | 1 | 1998 | 48 | 0.010 |
Why?
|
| Emulsions | 1 | 1998 | 19 | 0.010 |
Why?
|
| Postoperative Period | 1 | 1999 | 301 | 0.010 |
Why?
|
| Intestinal Absorption | 1 | 1998 | 125 | 0.010 |
Why?
|
| Cephalosporins | 1 | 1998 | 24 | 0.010 |
Why?
|
| Amino Acid Sequence | 2 | 1992 | 2064 | 0.010 |
Why?
|
| Intraoperative Complications | 2 | 1990 | 185 | 0.010 |
Why?
|
| Peritoneum | 1 | 1998 | 57 | 0.010 |
Why?
|
| Catheterization | 1 | 1999 | 237 | 0.010 |
Why?
|
| Aminosalicylic Acids | 1 | 1998 | 41 | 0.010 |
Why?
|
| Interleukin-4 | 1 | 1998 | 129 | 0.010 |
Why?
|
| Isotopes | 1 | 1957 | 26 | 0.010 |
Why?
|
| Cholangitis, Sclerosing | 1 | 1998 | 51 | 0.010 |
Why?
|
| Chromium | 1 | 1957 | 17 | 0.010 |
Why?
|
| Blood Group Incompatibility | 1 | 1997 | 21 | 0.010 |
Why?
|
| Molecular Sequence Data | 2 | 1992 | 3024 | 0.010 |
Why?
|
| Herpesviridae Infections | 1 | 1997 | 46 | 0.010 |
Why?
|
| Peer Review, Research | 1 | 1997 | 36 | 0.010 |
Why?
|
| Public Opinion | 1 | 1997 | 44 | 0.010 |
Why?
|
| Cell Movement | 1 | 2001 | 786 | 0.010 |
Why?
|
| Knee Prosthesis | 1 | 1997 | 32 | 0.010 |
Why?
|
| Liver Failure | 1 | 1997 | 68 | 0.010 |
Why?
|
| Colectomy | 1 | 1998 | 175 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 1996 | 270 | 0.010 |
Why?
|
| Angiography | 1 | 1996 | 208 | 0.010 |
Why?
|
| Avidin | 1 | 1995 | 5 | 0.010 |
Why?
|
| Belgium | 1 | 1995 | 3 | 0.010 |
Why?
|
| Viremia | 1 | 1995 | 49 | 0.010 |
Why?
|
| Ionomycin | 1 | 1995 | 21 | 0.010 |
Why?
|
| HLA-DR Antigens | 1 | 1995 | 59 | 0.010 |
Why?
|
| DNA | 1 | 2001 | 1311 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2001 | 1227 | 0.010 |
Why?
|
| Disease Progression | 1 | 1999 | 1469 | 0.010 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 1995 | 137 | 0.010 |
Why?
|
| Premedication | 1 | 1994 | 57 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 1999 | 1732 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 2 | 1998 | 2677 | 0.010 |
Why?
|
| Lectins, C-Type | 1 | 1994 | 86 | 0.010 |
Why?
|
| Bacteria | 1 | 1998 | 486 | 0.010 |
Why?
|
| Prevalence | 1 | 1998 | 1250 | 0.010 |
Why?
|
| Antiviral Agents | 1 | 1997 | 482 | 0.010 |
Why?
|
| Secretory Rate | 1 | 1993 | 13 | 0.010 |
Why?
|
| Succinic Acid | 1 | 1993 | 7 | 0.010 |
Why?
|
| Contrast Media | 1 | 1998 | 1084 | 0.010 |
Why?
|
| Succinates | 1 | 1993 | 21 | 0.010 |
Why?
|
| Spectrum Analysis | 1 | 1993 | 119 | 0.010 |
Why?
|
| Mucus | 1 | 1992 | 19 | 0.010 |
Why?
|
| Cholestasis | 1 | 1992 | 45 | 0.010 |
Why?
|
| Antigen-Antibody Reactions | 1 | 1992 | 23 | 0.010 |
Why?
|
| Cytotoxicity Tests, Immunologic | 1 | 1992 | 43 | 0.010 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 1992 | 42 | 0.010 |
Why?
|
| Antibody Formation | 1 | 1993 | 171 | 0.010 |
Why?
|
| Antibody Affinity | 1 | 1992 | 38 | 0.010 |
Why?
|
| Glycoside Hydrolases | 1 | 1952 | 17 | 0.010 |
Why?
|
| Binding, Competitive | 1 | 1992 | 146 | 0.010 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 1992 | 173 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 1999 | 2393 | 0.010 |
Why?
|
| Receptors, IgG | 1 | 1992 | 53 | 0.010 |
Why?
|
| Mycoses | 1 | 1992 | 46 | 0.010 |
Why?
|
| Pancreatic Juice | 1 | 1951 | 1 | 0.010 |
Why?
|
| Vagotomy | 1 | 1951 | 12 | 0.010 |
Why?
|
| Immunoglobulin Light Chains | 1 | 1992 | 91 | 0.010 |
Why?
|
| Immunoglobulin Heavy Chains | 1 | 1992 | 133 | 0.010 |
Why?
|
| Parasympatholytics | 1 | 1951 | 19 | 0.010 |
Why?
|
| Constriction, Pathologic | 1 | 1992 | 222 | 0.010 |
Why?
|
| Pepsin A | 1 | 1991 | 5 | 0.010 |
Why?
|
| Quaternary Ammonium Compounds | 1 | 1951 | 81 | 0.010 |
Why?
|
| Raffinose | 1 | 1991 | 23 | 0.010 |
Why?
|
| Transplantation, Autologous | 1 | 1993 | 347 | 0.010 |
Why?
|
| Models, Biological | 1 | 1998 | 1765 | 0.010 |
Why?
|
| Gastrectomy | 1 | 1951 | 71 | 0.010 |
Why?
|
| Immunization, Passive | 1 | 1991 | 71 | 0.010 |
Why?
|
| Antibody Specificity | 1 | 1991 | 130 | 0.010 |
Why?
|
| Peritonitis | 1 | 1991 | 29 | 0.010 |
Why?
|
| Contraindications | 1 | 1991 | 70 | 0.010 |
Why?
|
| Crohn Disease | 1 | 1998 | 764 | 0.010 |
Why?
|
| Glutathione | 1 | 1991 | 108 | 0.010 |
Why?
|
| Receptors, Cell Surface | 1 | 1992 | 288 | 0.010 |
Why?
|
| Neoplasms | 2 | 1993 | 3065 | 0.010 |
Why?
|
| Cholecystitis | 1 | 1950 | 16 | 0.010 |
Why?
|
| Lipoprotein(a) | 1 | 1991 | 30 | 0.010 |
Why?
|
| Colitis, Ulcerative | 1 | 1998 | 760 | 0.010 |
Why?
|
| Epitopes | 1 | 1991 | 254 | 0.010 |
Why?
|
| Plasminogen | 1 | 1991 | 45 | 0.010 |
Why?
|
| Morbidity | 1 | 1991 | 149 | 0.010 |
Why?
|
| Microsurgery | 1 | 1991 | 91 | 0.010 |
Why?
|
| Ultrasonics | 1 | 1990 | 39 | 0.010 |
Why?
|
| Body Weight | 1 | 1992 | 453 | 0.010 |
Why?
|
| Ethicists | 1 | 1990 | 20 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 1992 | 1048 | 0.010 |
Why?
|
| Triglycerides | 1 | 1991 | 233 | 0.010 |
Why?
|
| Bile Duct Diseases | 1 | 1990 | 23 | 0.010 |
Why?
|
| Intubation | 1 | 1990 | 21 | 0.010 |
Why?
|
| Cholesterol, HDL | 1 | 1991 | 168 | 0.010 |
Why?
|
| Blood Flow Velocity | 1 | 1990 | 200 | 0.010 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 1 | 1990 | 68 | 0.010 |
Why?
|
| Radiography, Abdominal | 1 | 1990 | 70 | 0.010 |
Why?
|
| Regression Analysis | 1 | 1991 | 591 | 0.010 |
Why?
|
| Suture Techniques | 1 | 1990 | 144 | 0.000 |
Why?
|
| Rats, Inbred BN | 1 | 1988 | 38 | 0.000 |
Why?
|
| Pulmonary Wedge Pressure | 1 | 1989 | 113 | 0.000 |
Why?
|
| Tissue Survival | 1 | 1988 | 13 | 0.000 |
Why?
|
| Cholesterol | 1 | 1991 | 360 | 0.000 |
Why?
|
| Free Radicals | 1 | 1988 | 71 | 0.000 |
Why?
|
| Abnormalities, Multiple | 1 | 1990 | 234 | 0.000 |
Why?
|
| Adenosine | 1 | 1991 | 240 | 0.000 |
Why?
|
| Kidney Function Tests | 1 | 1988 | 115 | 0.000 |
Why?
|
| Body Temperature | 1 | 1988 | 125 | 0.000 |
Why?
|
| Leukocyte Count | 1 | 1988 | 224 | 0.000 |
Why?
|
| Dogs | 2 | 1987 | 706 | 0.000 |
Why?
|
| Blood Urea Nitrogen | 1 | 1987 | 34 | 0.000 |
Why?
|
| Sepsis | 1 | 1991 | 329 | 0.000 |
Why?
|
| Stents | 1 | 1990 | 412 | 0.000 |
Why?
|
| Immunization | 1 | 1987 | 163 | 0.000 |
Why?
|
| Parents | 1 | 1989 | 290 | 0.000 |
Why?
|
| Body Mass Index | 1 | 1989 | 776 | 0.000 |
Why?
|
| Longevity | 1 | 1984 | 58 | 0.000 |
Why?
|
| Hemodynamics | 1 | 1987 | 738 | 0.000 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 1989 | 1352 | 0.000 |
Why?
|
| Genetic Linkage | 1 | 1981 | 624 | 0.000 |
Why?
|
| Pedigree | 1 | 1981 | 971 | 0.000 |
Why?
|
| Platelet Transfusion | 1 | 1952 | 16 | 0.000 |
Why?
|
| Blood Vessels | 1 | 1952 | 94 | 0.000 |
Why?
|
| Carbon | 1 | 1952 | 90 | 0.000 |
Why?
|
| Neovascularization, Pathologic | 1 | 1952 | 354 | 0.000 |
Why?
|
| Pregnancy | 1 | 1950 | 3048 | 0.000 |
Why?
|